Dr. Gilberto Lopes Appointed Chairman of First Ascent Biomedical's Medical Advisory Board
First Ascent Biomedical, a leader in precision oncology, has exciting news as it announces the appointment of Dr. Gilberto Lopes as the new Chairman of its Medical Advisory Board. Dr. Lopes brings a wealth of experience from his position as the Chief of the Division of Medical Oncology at the University of Miami Miller School of Medicine and as Associate Director for Global Oncology at the Sylvester Comprehensive Cancer Center, the only cancer center in South Florida designated by the National Cancer Institute (NCI).
Dr. Lopes is highly recognized in the field of oncology and clinical trials, having contributed to significant advancements in cancer treatment through his work in anticancer drug development, clinical research, cancer policy, and improving patient access to treatments. With over 300 published scientific papers and numerous clinical trials led under his guidance, he played a pivotal role in the FDA approval of pembrolizumab for advanced non-small cell lung cancer through the landmark KEYNOTE-042 clinical trial.
In his role at First Ascent Biomedical, Dr. Lopes will advise on the company's scientific strategies and the development of clinical evidence essential for moving Functional Precision Oncology forward. He will be instrumental in shaping health-economic research, designing future clinical studies, and interpreting clinical outcomes. His leadership will help First Ascent Biomedical adopt rigorous standards that bridge the gap between cutting-edge scientific advancements and patient care practices.
Jim Foote, co-founder and CEO of First Ascent Biomedical, remarked, "Dr. Lopes is a respected leader in oncology, working at the intersection of patient care and clinical research. His insights will be invaluable as we aim to transition Functional Precision Oncology into a valuable asset for clinical practice. We believe that scientific breakthroughs must be supported by robust evidence and trusted by healthcare professionals to have a meaningful impact on patient treatment decisions."
As Functional Precision Oncology continues evolving, Dr. Lopes’ expertise is especially timely. The field has seen significant recognition from organizations like the American Society of Clinical Oncology (ASCO), which has differentiated contemporary Functional Precision Medicine from older models. The urgent call for modern approaches and technologies, as stated in ASCO's recent communications, emphasizes the need for integrating functional testing alongside genomic profiling—something First Ascent Biomedical advocates through its innovative xDRIVE platform.
The xDRIVE platform employs live tumor or blood samples to test the responsiveness of cancer cells to various therapies. This process not only informs oncologists about potential treatment options but also aligns with advancements in genomics to facilitate individualized treatment plans. Dr. Lopes’ addition to the team is anticipated to expedite the development of a scientific framework for Functional Precision Oncology Centers of Excellence, expanding access to these pioneering treatment decision-support tools across diverse healthcare settings.
Dr. Lopes acknowledged the rigorous standards required within academic oncology and the importance of translating scientific innovations into clinical applications that reach patients effectively. He stated, "Functional Precision Oncology is at a pivotal stage where promising technologies must be supported by clinical evidence to ensure they can be integrated into everyday medical practice. Our goal is to provide oncologists with enhanced tools that complement their expertise and facilitate tailored treatments based on individual patient profiles."
As First Ascent Biomedical strives to enhance its offerings in Functional Precision Oncology and narrow the gap between research findings and clinical applications, the appointment of Dr. Gilberto Lopes marks a significant step forward. His extensive background and commitment to improving cancer treatment will surely help the company advance its mission of improving patient outcomes and access to effective therapies. This collaboration between First Ascent Biomedical and Dr. Lopes could usher in a new era of personalized medicine within oncology, where data-driven insights significantly inform clinical decision-making. Expect to see innovative developments as this new leadership seeks to bridge scientific research with practical healthcare solutions.
Dr. Lopes is highly recognized in the field of oncology and clinical trials, having contributed to significant advancements in cancer treatment through his work in anticancer drug development, clinical research, cancer policy, and improving patient access to treatments. With over 300 published scientific papers and numerous clinical trials led under his guidance, he played a pivotal role in the FDA approval of pembrolizumab for advanced non-small cell lung cancer through the landmark KEYNOTE-042 clinical trial.
In his role at First Ascent Biomedical, Dr. Lopes will advise on the company's scientific strategies and the development of clinical evidence essential for moving Functional Precision Oncology forward. He will be instrumental in shaping health-economic research, designing future clinical studies, and interpreting clinical outcomes. His leadership will help First Ascent Biomedical adopt rigorous standards that bridge the gap between cutting-edge scientific advancements and patient care practices.
Jim Foote, co-founder and CEO of First Ascent Biomedical, remarked, "Dr. Lopes is a respected leader in oncology, working at the intersection of patient care and clinical research. His insights will be invaluable as we aim to transition Functional Precision Oncology into a valuable asset for clinical practice. We believe that scientific breakthroughs must be supported by robust evidence and trusted by healthcare professionals to have a meaningful impact on patient treatment decisions."
As Functional Precision Oncology continues evolving, Dr. Lopes’ expertise is especially timely. The field has seen significant recognition from organizations like the American Society of Clinical Oncology (ASCO), which has differentiated contemporary Functional Precision Medicine from older models. The urgent call for modern approaches and technologies, as stated in ASCO's recent communications, emphasizes the need for integrating functional testing alongside genomic profiling—something First Ascent Biomedical advocates through its innovative xDRIVE platform.
The xDRIVE platform employs live tumor or blood samples to test the responsiveness of cancer cells to various therapies. This process not only informs oncologists about potential treatment options but also aligns with advancements in genomics to facilitate individualized treatment plans. Dr. Lopes’ addition to the team is anticipated to expedite the development of a scientific framework for Functional Precision Oncology Centers of Excellence, expanding access to these pioneering treatment decision-support tools across diverse healthcare settings.
Dr. Lopes acknowledged the rigorous standards required within academic oncology and the importance of translating scientific innovations into clinical applications that reach patients effectively. He stated, "Functional Precision Oncology is at a pivotal stage where promising technologies must be supported by clinical evidence to ensure they can be integrated into everyday medical practice. Our goal is to provide oncologists with enhanced tools that complement their expertise and facilitate tailored treatments based on individual patient profiles."
As First Ascent Biomedical strives to enhance its offerings in Functional Precision Oncology and narrow the gap between research findings and clinical applications, the appointment of Dr. Gilberto Lopes marks a significant step forward. His extensive background and commitment to improving cancer treatment will surely help the company advance its mission of improving patient outcomes and access to effective therapies. This collaboration between First Ascent Biomedical and Dr. Lopes could usher in a new era of personalized medicine within oncology, where data-driven insights significantly inform clinical decision-making. Expect to see innovative developments as this new leadership seeks to bridge scientific research with practical healthcare solutions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.